ITOS Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan iTeos

iTeos Therapeutics (ITOS) develops advanced cancer immunotherapy methods by blocking tumor defense mechanisms. The company's success relies on its partnership with GSK, although the risks of clinical trial failures remain significant. The business model is based on outsourced production, making the tracking of quarterly EPS growth a critical analytical tool, while the -903.70 metric confirms the current level of profit dynamics.

This indicator calculates the percentage change in net earnings per share between the current and previous quarter, measuring the rate of shareholder value generation. By analyzing the quarterly EPS trend profile, an investor can assess the impact of belrestotug antibody expansion costs and the partnership with GSK on the financial results of iTeos Therapeutics (ITOS), avoiding entry into the asset at the peak of anomalous growth.